Recombinant osteoprotegerin (OPG) promoted the adhesion of both primary polymorphonuclear neutrophils (PMN) and leukemic HL60 cells to endothelial cells.
Introduction
Osteoprotegerin (OPG), a soluble member of the TNF receptor superfamily, has been originally characterized for its ability to suppress osteoclast formation.
1 OPG inhibits osteoclastogenesis by binding to receptor activator of NF-kB ligand (RANKL), a member of the TNF superfamily of cytokines, and preventing the interaction of RANKL with its high-affinity transmembrane receptor namely receptor activator of NF-kB (RANK). 2 It has been shown that in the low nanomolar range, the binding interaction of OPG and RANKL is 1:1 (or some multiple thereof) 3 and that dimerization of OPG results from noncovalent interactions mediated by the death domains and to a lesser extent by a C-terminal heparin-binding region. OPG dimer formation is required for the mechanism of inhibition of the RANKL/RANK receptor interaction.
3
OPG can also interact with another member of the TNF superfamily, TNF-related apoptosis inducing ligand (TRAIL), 4 which shows the ability to kill a variety of cancer cell types both in vivo and in vitro. 5 A role for OPG as a neutralizing receptor for TRAIL under physiological conditions has been questioned in early studies, but there is now mounting evidence suggesting that the OPG/TRAIL interaction is biologically important, at least in in vitro culture systems. 6 OPG has been shown to act in a paracrine or autocrine manner by binding TRAIL and promoting the survival of prostate cancer cells, 7 breast cancer cells, 8 and multiple myeloma cells. 9 Moreover, when a rationally designed small molecule mimic of OPG was examined for association with TRAIL or RANKL in binding studies, this peptide bound to RANKL at a Kd of 3.89x10 -6 M and to TRAIL at a Kd of 1.93x10 -5 M, showing only about 5-fold higher affinity for recombinant RANKL compared to recombinant TRAIL.
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A number of studies have clearly demonstrated that the serum levels of OPG are elevated in both diabetic and non-diabetic patients affected by coronary artery disease and heart failure after acute myocardial infarction, and increased levels of OPG in these patients represent a risk factor for cardiovascular mortality.
11-18 OPG serum levels are also elevated in patients affected by a variety of human malignancies, including hematological disorders 19, 20 and an immuno-histochemical study has demonstrated that OPG is expressed in the tumor-associated endothelium in approximately 60% of malignant tumors.
21
In spite of the reported findings, the physiopathological role of elevated serum levels of OPG in vascular biology is not well understood. On these bases, we have investigated the effect of OPG on the endothelial-leukocyte interactions both in in vitro and in vivo experimental models.
Methods

All the animal experimental procedures were performed in compliance with the guidelines of European (86/609/EEC) and the Italian (D.L.116/92) laws and approved by the Italian Ministry of University and Research as well as by the
Cells and reagents
Primary human umbilical vascular endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC) were obtained from BioWittaker (Walkersville, MD). HUVEC and HMVEC were used between the 2 nd and 5 th passage in vitro and were cultured in EGM basal medium supplemented with 2% FBS, 12 mg/ml BBE, 1 mg/ml hydrocortisone and 10 ng/ml ECGF (all from BioWhittaker), as previously described.
22,23
EDTA-blood samples for the isolation of primary polymorphonuclear neutrophils (PMN) were drawn from healthy volunteers after obtaining informed consent . Blood samples were diluted 1:2 with PBS and a first separation step was performed by Heparin, heparinases I, II, III, chondroitinase ABC were purchased from Sigma Chemicals (St Louis, MO). Tumor necrosis factor-α (TNF-α) and recombinant OPG were from R&D Systems (Minneapolis, MN). In particular, the recombinant full-length OPG (Met 1-Leu 401) was expressed in the NSO mouse myeloma cell line. After purification, the recombinant OPG, a disulphide-linked homodimeric protein generated after removal of a 21 amino acid signal peptide from each monomer, is lyophilized from a 0.2 µm filtered solution in PBS ("carrier free"). In selected experiments, we have also used the recombinant OPG-Fc, corresponding to the cysteine-rich region of human OPG (aa fused to the Fc portion of human IgG1, therefore lacking the N-terminal heparin-binding domain.
Human OPG levels were measured in HUVEC culture supernatants using sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (purchased from Alexis Biochemicals, Lausen, Switzerland), according to the manufacturers' instructions. The results were read using an Anthos 2010 ELISA reader (Anthos Labtec Instruments Ges.m.b.H, Austria). Measurements were done in duplicates.
Endothelial-leukocyte adhesion assay
Vascular endothelial cells were grown to confluence in 24 or 96-well tissue culture plates and stimulated for 1 min to up 16 hours (overnight) at 37°C with recombinant human OPG or TNF-α, used alone or in combination. After 3 washings with serum-free medium, untreated 1-3.5 10 5 PMN or HL60 cell suspensions were added to each well and were further incubated at 37°C for 60 min. In some experiments, leukocytes were added simultaneously with recombinant OPG to HUVEC for up to 60 min. After endothelial-leukocyte co-culture, non-adherent PMN or HL60 cells were removed by washing the wells at least twice. Endothelial-leukocyte co-cultures were 
Statistical analysis
The results were evaluated by using analysis of variance with comparison by Student's t-test and with the Mann-Whitney rank-sum test. Statistical significance was defined as p<0.05.
Results
Recombinant OPG promotes the leukocyte/endothelial cell adhesion
Our initial experiments were designed to investigate whether OPG might affect leukocyte/endothelial interactions. HUVEC were grown to confluence and incubated with increasing concentrations (0.01-10 ng/ml) of recombinant human OPG. In parallel, cells 
Leukocytes adhere to endothelium in vivo in response to OPG
In the last group of experiments, we sought to determine whether OPG was able to promote leukocyte adhesion to endothelial cells also in vivo. Recombinant OPG (1-10 ng/ml) was topically applied to the rat mesentery and after 4 hours the rolling and adhesion of leukocytes was determined by intravital microscopy at different time points (30-60-90 min). This is a previously established in vivo procedure, through which single polypeptides as well as big protein complexes easily enter in the blood circulation through the highly permeable post-capillary venules of the rat mesentery. 24 As shown in Thus, the picture emerging from these previous studies is quite complex: while a basal constitutive production/release of OPG by vascular smooth muscle cells and endothelial cells is essential to protect the vessel wall against calcification, an increased release of OPG correlates to increased cardiovascular risk.
11-18
In this study, we have demonstrated for the first time that the treatment of vascular endothelial cells with recombinant OPG promotes the adhesion of both primary PMN and leukemic HL60 cells to the endothelial cell surface. Interestingly, the greatest effect was observed at concentrations of OPG comprised in the same range of those described to be elevated in the serum of patients affected by cardiovascular diseases.
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The ability of OPG to promote leukocyte adhesion to endothelial cells was very rapid (5-15 min). A similar increase of pro-adhesion activity was observed when PMN rather than HUVEC were pre-treated with OPG before the co-culture incubation. In this respect, it is noteworthy that both PMN and HL60 exhibit significant surface levels of both RANKL and TRAIL while endothelial cells, obtained by different sources, did not show surface expression of the high-affinity transmembrane ligands of OPG. Therefore, OPG likely interacts through its ligand-binding domain with RANKL and/or TRAIL expressed on the surface of leukocytes. On the other hand, the data obtained pre-treating OPG with heparin before the adhesion assays strongly suggest that OPG interacts with endothelial cell membrane through its heparin-binding domain. In this respect, it should be mentioned that the heparan sulfates expressed on the cell surface are important participants in cellsurface signaling and have been involved in actin cytoskeleton regulation, cell adhesion and migration, and modulation of specific receptor interactions.
37,38 It should also be underlined that the interaction between OPG and glycosaminoglycans was confirmed in a recent study by surface plasmon resonance, which demonstrated that OPG binds to heparin with a high-affinity (KD: 0.28 nM).
28
By using intravital microscopy, which provides a useful tool for observing leukocyte-endothelium interactions in vivo, we have also demonstrated that the findings obtained in vitro are relevant in vivo since leukocytes circulating in the rat mesentery under physiological flow conditions firmly adhered to the endothelium of the postcapillary venules after the topical administration of recombinant OPG. Since an abnormal increase of leukocyte adhesion to endothelial cells is considered an early step in endothelial cell dysfunction, 39 the results illustrated in our study suggest a potential mechanism to explain why pathologically elevated serum OPG levels are linked to the development or status of vascular disease. In fact, a number of reports have shown that
18
increased circulating OPG levels often occur in cardiovascular diseases.
11-18 Moreover, linkage of two OPG genetic polymorphisms was associated with an increased risk of coronary artery disease in Caucasian men, and serum OPG levels correlated with one of these polymorphisms.
40
Studies of other authors have shown that OPG is an NF-kB-inducible gene, whose expression and release in culture of vascular cells is significantly increased by inflammatory cytokines.
30-33
In this respect, we have confirmed that TNF-α potently induced the release in HUVEC culture of endogenous OPG. Although it cannot be excluded that the increased release of OPG in response to inflammatory cytokines might merely represent a bystander effect or even an attempt to counteract the endothelial damage induced by inflammatory cytokines, our present data rather suggest that elevated levels of OPG might substantially contribute to establish a vicious inflammatory circle by enhancing the pro-adhesive activity of TNF-α. Since we have recently demonstrated that the systemic administration or recombinant TRAIL shows anti-atherosclerotic activity in apolipoprotein E-null diabetic mice, 41 an alternative not mutually exclusive mechanism by which elevated levels of serum OPG might contribute to cardiovascular risk is by inhibiting the anti-atherosclerotic activity of circulating TRAIL.
Our present findings are particularly noteworthy also considering the enormous surface area of the endothelium throughout the body, which suggests that endothelial cells are a key cell type involved in the production/release of circulating OPG in human serum.
33,42
Although previous studies have reported the possibility that OPG may affect relevant cell parameters, such as release of matrix metalloproteinase-9 (MMP-9) activity, 34 this is the first study to the best of our knowledge that demonstrates the ability of OPG to markedly increase the leukocyte-endothelial interactions both in vitro and in vivo. Overall, our study suggests how the enhanced OPG production and release 
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